U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07037758) titled 'A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)' on June 17.
Brief Summary: The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248.
The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.
Study Start Date: July 18
Study Type: INTERVENTIONAL
Condition:
Extensive Stage Small Cell Lung Cancer
Intervention:
DRUG: Tarlatamab
Administered ...